Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 15
2003 24
2004 11
2005 18
2006 27
2007 11
2008 22
2009 23
2010 16
2011 23
2012 9
2013 17
2014 19
2015 24
2016 29
2017 21
2018 16
2019 15
2020 5
2021 3
2022 4
2023 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Results by year

Filters applied: . Clear all
Page 1
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Thompson PA, Bazinet A, Wierda WG, Tam CS, O'Brien SM, Saha S, Peterson CB, Plunkett W, Keating MJ. Thompson PA, et al. Among authors: keating mj. Blood. 2023 Nov 23;142(21):1784-1788. doi: 10.1182/blood.2023020158. Blood. 2023. PMID: 37595283 Free PMC article.
We updated long-term follow-up results from the original 300-patient FCR study initiated at MD Anderson in 1999. The current median follow-up is 19.0 years. With this extended follow-up, the median PFS for patients with IGHV-M was 14.6 years vs 4.2 years for patients with …
We updated long-term follow-up results from the original 300-patient FCR study initiated at MD Anderson in 1999. The current median f …
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Thomas DA, et al. Among authors: keating mj. J Clin Oncol. 2010 Aug 20;28(24):3880-9. doi: 10.1200/JCO.2009.26.9456. Epub 2010 Jul 26. J Clin Oncol. 2010. PMID: 20660823 Free PMC article. Clinical Trial.
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Thomas DA, et al. Among authors: keating mj. Cancer. 2006 Apr 1;106(7):1569-80. doi: 10.1002/cncr.21776. Cancer. 2006. PMID: 16502413 Free article. Clinical Trial.
Richter transformation of CLL.
Jain N, Keating MJ. Jain N, et al. Among authors: keating mj. Expert Rev Hematol. 2016 Aug;9(8):793-801. doi: 10.1080/17474086.2016.1199948. Epub 2016 Jun 28. Expert Rev Hematol. 2016. PMID: 27351634 Review.
Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Abou Zahr A, Bose P, Keating MJ. Abou Zahr A, et al. Among authors: keating mj. Expert Opin Pharmacother. 2017 Jun;18(9):857-873. doi: 10.1080/14656566.2017.1324420. Epub 2017 May 16. Expert Opin Pharmacother. 2017. PMID: 28446054 Free PMC article. Review.
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia.
Zhang R, Khare P, Banerjee P, Ivan C, Schneider S, Barbaglio F, Clise-Dwyer K, Jensen VB, Thompson E, Mendoza M, Chiorazzi N, Chen SS, Yan XJ, Jain N, Ghia P, Caligaris-Cappio F, Mendonsa R, Kasimsetty S, Swoboda R, Bayraktar R, Wierda W, Gandhi V, Calin GA, Keating MJ, Bertilaccio MTS. Zhang R, et al. Among authors: keating mj. Blood Cancer J. 2024 Oct 23;14(1):168. doi: 10.1038/s41408-024-01142-3. Blood Cancer J. 2024. PMID: 39438453 Free PMC article.
Metabolism pathways in chronic lymphocytic leukemia.
Rozovski U, Hazan-Halevy I, Barzilai M, Keating MJ, Estrov Z. Rozovski U, et al. Among authors: keating mj. Leuk Lymphoma. 2016;57(4):758-65. doi: 10.3109/10428194.2015.1106533. Epub 2015 Dec 8. Leuk Lymphoma. 2016. PMID: 26643954 Free PMC article. Review.
Retrospect of hematological malignancies 2012.
Freireich EJ, Kantarjian H, Keating MJ. Freireich EJ, et al. Among authors: keating mj. Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S271. doi: 10.1016/j.clml.2013.08.001. Clin Lymphoma Myeloma Leuk. 2013. PMID: 24290211 No abstract available.
Toward the potential cure of leukemias in the next decade.
Kantarjian HM, Keating MJ, Freireich EJ. Kantarjian HM, et al. Among authors: keating mj. Cancer. 2018 Nov 15;124(22):4301-4313. doi: 10.1002/cncr.31669. Epub 2018 Oct 6. Cancer. 2018. PMID: 30291792 Free article. Review.
305 results